Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Status:
Completed
Trial end date:
2021-07-23
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the
administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r
DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and
anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The
study will consist of 2 parts: dose timing selection part and expansion part.